Four-in-One HIV Pill Enters Late-Stage Clinical Testing
April 13, 2010
"Gilead Sciences Inc. said Monday it started late stage clinical testing of its four-in-one 'Quad' HIV tablet," the Associated Press reports. The pill includes the drugs elvitegravir, cobicistat, and the two components of Truvada, emtricitabine and tenofovir (4/12). "The Phase III clinical program for the Quad includes two studies ... that will evaluate the Quad regimen versus a standard of care among" HIV-positive adults who have not yet started antiretroviral treatment, according to a Gilead press release (4/12).
"Quad" Pill Continues to Impress in Week-48 Results; Cobicistat Moves Forward in Battle With Ritonavir
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)